GSK Aims Flonase Sensimist To Counter Generic Nasal Allergy Competition

GlaxoSmithKline Flonase Sensimist Allergy Relief could help fend off private label competition in the intranasal corticosteroid category, the firm says. Despite a 19% drop in sales of the original Flonase OTC in the fourth quarter, US consumer health care sales grew 5% to $2.2bn on a reported basis in 2016.